stem cell transplantation; critical care; drotrecogin alfa (activated); safety Activated protein C, an endogenous human protein, promotes fibrinolysis and inhibits inflammation and coagulation associated with severe sepsis. Severe deficiency of protein C is associated with increased mortality in patients with severe sepsis. 1 Drotrecogin alfa (activated) (Drot AA), a recombinant form of human activated protein C, was demonstrated in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial to reduce all-cause mortality in severe sepsis. 2 This agent was approved by the US Food and Drug Administration (FDA) in November 2001 for the treatment of severe sepsis in adults at a high risk of death in addition to standard care. The only safety concern noted was an increased rate of serious bleeding among Drot AA-treated patients compared to those who received placebo (2.4 vs 1.0% during study-drug infusion, and 3.5 vs 2.0%, respectively, over the 28-day study period).
Adult hematopoietic stem cell transplantation (HSCT) patients who develop septic shock and respiratory failure requiring vasoactive therapy and mechanical ventilation, respectively, generally have poor outcomes with mortality rates ranging from 63% to greater than 90%. [3] [4] [5] [6] [7] [8] Similar to severe sepsis, significant decreases in the level of protein C and other natural anticoagulants have been associated with the multiple organ dysfunction syndrome during HSCT. 9 HSCT patients, however, were excluded from the PRO-WESS trial because of the inherent risk of bleeding due to thrombocytopenia and altered endothelium 10 and the high probability of dying within 28 days from a nonseptic related cause. Thus, the safety and efficacy of Drot AA in this population is unknown. To our knowledge, there is one single case report of successful use of Drot AA in a patient with severe sepsis following HSCT. 11 The purpose of this study was to evaluate the safety and efficacy of Drot AA in HSCT patients with severe sepsis.
Methods
This study was a prospective, single country (US), multicenter, open-label trial of Drot AA in adult HSCT patients with severe sepsis. The target enrollment was 250 patients at 15-20 transplant centers over a 2-year period. The study was approved by the institutional and/or ethical review boards at each of the 15 participating university centers. Written informed consent was obtained from all patients or their authorized representatives.
The inclusion and exclusion criteria are shown in Tables  1 and 2 . Severe sepsis was defined as sepsis associated with acute organ dysfunction. To be eligible for enrollment in this study, patients had to have suspected or proven infection, vasopressor-dependent shock and/or ventilatordependent respiratory failure of 48 h or fewer duration and must have received the HSCT conditioning regimen within 60 days.
Interventions
All patients were scheduled to receive Drot AA (Xigris & , Eli Lilly and Co., Indianapolis, IN, USA) at a dose of 24 mg/kg/h as a continuous i.v. infusion for 96 h. The study-drug infusion was to be held for platelet counts o30 000/mm 3 or serious bleeding.
Trial measurements
The primary objective of this trial was to investigate the safety of Drot AA in HSCT patients with severe sepsis. The primary safety end point was to be assessed using the rate of intracranial hemorrhage (ICH) over the 100-day period following HSCT. A diagnosis of ICH would be confirmed if a patient had a sudden focal neurologic deficit accompanied by hemorrhage on computed tomography or magnetic resonance imaging or at autopsy. We projected that the ICH rate for HSCT patients treated with Drot AA could be as high as double the 2% historical ICH rate reported for HSCT patients during the first 100 days after HSCT.
12,13
The sample size of 250 patients was derived to allow for an estimate of the ICH incidence rate with 95% confidence to be within 2.5% from the assumed rate (472.5%). Secondary objectives included the investigation of serious adverse bleeding events (other than ICH) and assessment of mortality at 28 days from the start of studydrug infusion and at 100 days after HSCT.
The primary and secondary endpoints were to be compared to historical controls. Historical control data was obtained from the International Bone Marrow Transplant Registry database (IBMTR) and the Autologous Blood and Marrow Transplant Registry (ABMTR) (http://www.ibmtr.org, accessed April 12, 2005) .
Since this was an open-label study, review of safety data was performed on a continual basis throughout the trial.
Prospectively defined safety suspension rules were designed such that the trial could be stopped as early as five patients if there were two patients with ICH and all five patients died. In any circumstance, no more than 15 patients with ICH would be allowed to occur for the entire trial.
Enrollment began in March 2003 and ended in December 2003, when the study was stopped due to low enrollment. Of the 15 sites, 13 (87%) had the study-drug shipped to them at least 5 months before the study was stopped. However, only three of the 15 sites were able to successfully enroll patients, with a total accrual of seven patients during the 10-month study period. The sponsor and the primary investigators were in agreement that reaching the proposed sample size of 250 patients in a timely manner was not feasible. Study data was source verified and data lock occurred in April 2004.
Results
Seven patients were enrolled. The clinical characteristics of the patients are summarized in Table 3 . The 96-h Drot AA infusion was completed in six patients. The nadir platelet count during the Drot AA infusion is shown in Table 3 . Three patients survived to 100 days after the HSCT and four died: three from severe sepsis and one from an intracranial hemorrhage.
Two patients experienced serious bleeding events. The first patient (Table 3 , patient 1) experienced a moderate pulmonary hemorrhage on the second day of infusion. At that time, the platelet count was 52 000/mm 3 and the PT and aPTT were 12.6 and 27.2, respectively. The Drot AA infusion was stopped for approximately 24 h and then resumed until completion of the planned 96-h infusion without further bleeding. However, 2 days later the patient developed acute respiratory failure requiring mechanical ventilation. Fiberoptic bronchoscopy demonstrated diffuse alveolar hemorrhage and larval forms of Strongyloides. The patient was transfused platelets and administered an intravenous infusion of epsilon-aminocaproic acid. The patient subsequently developed multiorgan failure and expired 3 weeks later after supportive care was withdrawn. Table 1 Inclusion criteria
Patients enrolled in this study had to fulfill the following three criteria (A, B, C): Criteria A: Treated with a recent (p60 days) HSCT conditioning regimen for a hematologic malignancy such as leukemia, lymphoma or myeloma. Criteria B: Known or suspected infection. Proven infection confirmed by a positive microbial or viral culture. Patients with suspected infection must have had evidence of an infection such as white blood cells in a normally sterile body fluid, perforated viscus, chest X-ray consistent with pneumonia, or a clinical syndrome associated with a high probability of infection (eg, ascending cholangitis). Criteria C: Vasopressor-dependent septic shock (need for vasopressors to maintain systolic blood pressure X90 mmHg or mean arterial pressure X70 mmHg despite adequate fluid resuscitation) or ventilator-dependent respiratory failure. The second patient (Table 3 , patient 3) developed a sudden onset of neurologic deterioration on the third day of the infusion. Of note, the Drot AA infusion had been discontinued approximately 8 h prior to these neurological findings due to a marked prolongation of the PT (30 s) and aPTT (176 s) and a platelet count of 53 000/mm 3 . The patient was transfused platelets and plasma and the subsequent platelet count rose to 102 000/mm 3 . However, the severe coagulopathy persisted. A head CT confirmed a large intracerebral hemorrhage and the patient died 2 days later.
Discussion
In this study, three out of seven patients survived beyond 100 days post HSCT. It is difficult to determine whether Drot AA contributed to the survival of these three patients. Two of the four patients who died experienced serious bleeding events. While Drot AA may have contributed to the bleeds, there were simply too few patients in this study to form any conclusion regarding the safety of Drot AA in HSCT patients. Likewise, the limited number of patients precludes any definitive statement regarding the efficacy of Drot AA in HSCT patients with severe sepsis.
This study was designed as a phase IV, open-label, clinical trial for HSCT patients with severe sepsis. A randomized placebo-controlled trial would have been ideal. However, we felt that given the high mortality associated with HSCT patients with severe sepsis and the fact that Drot AA was an FDA-approved agent for severe sepsis, an expedited safety trial was warranted.
Accrual of patients in this study, however, was much slower than anticipated. While it is difficult to determine exactly why enrollment was limited, we hypothesized that there were four contributory factors. First, HSCT protocols were evolving from conventional conditioning regimens associated with early post-HSCT infections to nonmyeloablative regimens where early infectious complications are minimized. 14, 15 Second, enhancements in HSCT antimicrobial prophylactic regimens were introduced, potentially decreasing the incidence of severe sepsis. [16] [17] [18] [19] Third, the number of prospective patients may have been reduced by the increasing use of antibiotic-coated catheters 20 and other advances in the general care of severe sepsis. 21 Finally, clinicians may have been reluctant to enroll patients because of their concerns regarding the safety of Drot AA.
In general, clinical trials may be terminated because of problems related to efficacy, safety, feasibility and financial support (http://www.wma.net, accessed May 15, 2005) . 22, 23 This trial was stopped early by the study sponsor in accordance with standard clinical trial guidelines that emphasize the obligation to discontinue any study immediately when it becomes apparent that achieving study end points are not feasible. 24 After this failed trial, what is the role of Drot AA in the HSCT patient population where severe sepsis is a common cause of death? It is uncertain whether another study with Drot AA in this unique patient group will be attempted again in the future. However, given the high morbidity and 
